• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600812.SS
Share

North China Pharmaceutical Company.Ltd Stocks

CN¥ 4.82Last Updated 14.07.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

CN¥ 1.17B

CN¥ 4.82
Key Takeaways

Risk factor

Low price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Good growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

North China Pharmaceutical Company Ltd. is a Chinese firm specializing in the chemical pharmaceutical sector. Its extensive product range primarily features anti-infective medications, supplied as active pharmaceutical ingredients (APIs), their intermediates, and final preparations. The company's offerings further encompass biotechnological therapeutics, drugs for cardiovascular conditions, immunomodulators, vitamin-based consumer health products, and specialized pharmaceuticals for agricultural and veterinary applications. Founded in 1953, North China Pharmaceutical Company Ltd. maintains its headquarters in Shijiazhuang, China.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBITD

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 11:10

Oil prices soared to a one-month high following new attacks by the U.S. and Iran in the Strait of Hormuz

14.07.2026 10:44

Intraday volatility: SK Hynix shares rebounded after a 9% plunge

14.07.2026 10:38

Morning Highlights: Oil Prices Rise Amid Strikes on Iran; Nvidia Tightens Export Controls

14.07.2026 09:30

Sam Altman "took the scam to a whole new level": Musk comments on Apple's lawsuit against OpenAI

14.07.2026 08:30

Disney's decision to abandon streaming will boost its stock by 40% — Wells Fargo

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026